Cannabis Reduces Non-Hodgkin Lymphoma Tumor Growth

Cannabis Agonist Reduces Non-Hodgkin Lymphoma Tumor Growth, Study Says

June 26, 2008 - Stockholm, Sweden

Stockholm, Sweden: The administration of the cannabinoid agonist R(+)-MA halts the spread and growth of cancerous tumors in animals with non-Hodgkin lymphoma, according to preclinical data published in the current issue of the International Journal of Cancer. Investigators at the Karolinska Institute in Stockholm reported that mice treated with R(+)-MA experienced a 40 percent reduction in tumor weight.

"The anti-proliferative and proapoptotic (stimulated cell death) effects of cannabinoids make the endocannabinoid system a potential new therapeutic target for individualized therapy in lymphomas," authors concluded.

Earlier this year, the journal Cancer Research reported that the administration of cannabinoids halts the spread of a wide range of cancers, including prostate cancer, breast cancer, lung cancer, pancreatic cancer, and brain cancer.

NORML Deputy Director Paul Armentano has a review of pot's anti-cancer properties online at the Huffington Post.

For more information, please contact Paul Armentano, NORML Deputy Director. Full text of the study, "Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation," appears in the September issue of the International Journal of Cancer.

Cannabis Agonist Reduces Non-Hodgkin Lymphoma Tumor Growth, Study Says - NORML

If you found this article interesting please subscribe for updates with any reader or your email. This site is not monetized and 100 percent free. My only form of payment is my readers comments and subscriptions.